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Abstract
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Genomic studies of pediatric cancer have primarily focused on specific tumor types or high-risk
disease. Here, we used a three-platform sequencing approach, including whole genome (WGS),
exome, and RNA sequencing, to examine tumor and germline genomes from 309 prospectively
identified children with newly diagnosed (85%) or relapsed/refractory (15%) cancers, unselected
for tumor type. Eighty-six percent of patients harbored diagnostic (53%), prognostic (57%),
therapeutically-relevant (25%), and/or cancer predisposing (18%) variants. Inclusion of WGS
enabled detection of activating gene fusions and enhancer hijacks (36% and 8% of tumors,
respectively), small intragenic deletions (15% of tumors) and mutational signatures revealing of
pathogenic variant effects. Evaluation of paired tumor-normal data revealed relevance to tumor
development for 55% of pathogenic germline variants. This study demonstrates the power of
a three-platform approach that incorporates WGS to interrogate and interpret the full range of
genomic variants across newly diagnosed as well as relapsed/refractory pediatric cancers.
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INTRODUCTION
High throughput next generation sequencing (NGS) of pediatric cohorts has provided
seminal insights into the genomic landscapes of the major subtypes of childhood
cancer. It is now well established that these NGS approaches add significant value
by refining or changing cancer diagnoses(1–5), providing prognostic information(3,6),
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identifying therapeutic targets or markers of therapy resistance(2,3,5,7,8), detecting variants
of pharmacogenetic significance(3), and uncovering underlying genetic predisposition(2–
5,8,9).
To date, most pediatric NGS studies have focused on patients with high-risk disease,
including difficult-to-treat or relapsed/refractory cancers. In many of these studies, patients
with newly diagnosed or standard risk cancers are absent or underrepresented. However,
many standard risk cancers do not respond or recur following treatment with current
best available therapies. Indeed, such is the case for 15 – 20% of acute lymphoblastic
leukemia (ALL)(10) or Wilms tumor(11) cases and over 30% of rhabdomyosarcomas(12)
or other non-CNS solid tumors. To improve upon these outcomes, it is essential that we
comprehensively examine and elucidate the molecular underpinnings of childhood cancer
across the full spectrum of presentations.

Author Manuscript

Each childhood cancer harbors a unique combination of somatic alterations on a background
of inherited and de novo germline variants. Moreover, novel diagnostic and prognostic
subgroups and the full constellation of genetic drivers are yet to be defined for many rare
pediatric cancers. As such, an individual pediatric cancer genome could be described as
an “N of 1” case study for which genome-wide analysis can uncover unique molecular
drivers and elucidate how individual combinations of somatic and germline variants
influence clinical presentation and response to cancer therapy. Therefore, it is essential that
comprehensive genomic data are generated and systematically investigated if we are to fully
capitalize on the potential of precision medicine across pediatric cancers, including those
that are common as well as those that are rare.
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Prior studies using distinct sequencing platforms have demonstrated that a genome-wide
approach is necessary to enable full discovery of novel driver variants in pediatric
cancers(1,5,8,13–15). Towards this end, we developed a three-platform sequencing pipeline
that includes whole genome sequencing (WGS), whole exome sequencing (WES) and
RNA sequencing (RNA-Seq) of paired tumor and normal samples. This three-platform
pipeline has been validated on a retrospective cohort of highly selected high-risk pediatric
cancer cases harboring known genomic alterations as shown by classical molecular assays.
Furthermore, it greatly improved the accuracy of detection of genomic alterations, obviated
the need for validation testing of somatic and germline variants through orthogonal
approaches, and facilitated discovery of novel oncogenic processes(14).
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Here we present data from “Genomes for Kids” (G4K), a prospective non-therapeutic
three-platform sequencing study of 309 pediatric cancer patients, unselected for tumor type
or stage, treated at St Jude Children’s Research Hospital. The aims of this study were
to: 1) demonstrate the utility of comprehensive whole genome, exome, and transcriptome
sequencing of paired tumor and normal samples for patients across the spectrum of
standard risk to high risk cancers; 2) show how integrating data from multiple sequencing
platforms can elucidate the functional impacts of difficult-to-interpret variants; 3) analyze
rare genomic findings in N of 1 cases and show how these findings inform understanding of
tumor biology and, when possible, patient care; and 4) discover novel mechanisms driving a
diverse array of childhood cancers.

Cancer Discov. Author manuscript; available in PMC 2022 April 03.

Newman et al.

Page 3

Author Manuscript

RESULTS
Patient enrollment
From August 2015 to March 2017, 365 pediatric cancer patients were approached for
enrollment in G4K (NCT02530658), a non-therapeutic study of three-platform sequencing
of paired tumor and normal samples. Three hundred nine (85%) agreed to participate, 53
(15%) declined and three were later removed from the study (Fig. 1A). Race/ethnicity was
the only variable that significantly correlated with declining enrollment, with families of
black children more likely to decline compared to families of non-Hispanic or Hispanic
white children, p<0.001, as we have reported elsewhere(16).

Author Manuscript

Forty-seven patients did not undergo tumor biopsy for safety reasons or because biopsy was
not considered clinically indicated. Nine patients did not have sufficient tumor DNA or RNA
to complete three platform sequencing. Thus, 253 of 309 (82%) enrolled patients had their
tumors examined using WGS, WES and RNA-Seq. Nine of 309 patients’ families (3%)
declined the return of germline results, leaving 300 who underwent analysis of germline
samples using WES and WGS, followed by in depth evaluation and reporting of 156
cancer predisposition genes. Study participants included 166 males and 143 females with
an average age at cancer diagnosis of 7.4 years (range: 4 days to 25.7 years, Fig. 1B)
(Supplemental Table S1).
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At the time of G4K enrollment, 262 patients (85%) had newly diagnosed cancers and
47 (15%) had relapsed or refractory disease (Fig. 1C). The spectrum of cancers in the
G4K cohort was similar to that observed in the NCI SEER registry (Fig. 1D), except for
Hodgkin and non-Hodgkin lymphoma, which were underrepresented, and leukemia and
retinoblastoma, which were overrepresented. One hundred twenty-eight patients (41%) had
hematological malignancies of 28 subtypes, 97 (31%) had brain tumors of 27 subtypes, and
84 (27%) had non-CNS solid tumors of 26 subtypes. Forty-five patients (15%) had 18 very
rare tumor types, defined here as tumors present in fewer than 2 cases per million annually
in the United States (Fig. 1E). Among these 18 tumor types, only craniopharyngioma(17)
and mixed phenotype acute leukemia(18) have been studied in enough detail to provide
an initial understanding of associated somatic alterations. Thus, the ability to examine the
impact of genomic lesions in an N of 1 context is of paramount importance to understand the
biologic basis and therapeutic targets in these very rare tumors.
Overview of somatic alterations
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Tumor samples were evaluated using 45X PCR-free WGS and 150X WES from DNA and
100 million RNA-Seq reads from total RNA. Paired germline samples were evaluated using
both WGS and WES. Twelve hundred genes known to play a role in the pathogenesis
of cancer were interrogated using tumor genomic data. Genes were considered in the
context of each patient’s tumor type and prioritized for review, as previously described(19).
Given the potential effects of structural events and gene fusions on protein expression and
function, we reported novel events if there was strong sequence support and the structural
event or gene fusion involved genes of potential relevance to cancer. We detected somatic
single nucleotide variants (SNVs), small insertions/deletions (indels), loss of heterozygosity
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(LOH), structural variants (SVs) including fusions, enhancer hijacks, internal tandem
duplications (ITDs), and copy number alterations (CNAs) using automated computational
pipelines followed by analyst curation(14). Among the SNVs and indels observed on both
WGS and WES platforms, 41% had a variant allele fraction (VAF) below 0.2 and 15% had a
VAF below 0.1, revealing a large set of sub-clonal variants, including P/LP variants in both
SNV and indels, using this approach (Supplemental Figs. S1A, B).
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All variants were reviewed by a committee of computational biologists, pathologists,
oncologists, geneticists and genetic counselors. Reportable P/LP alterations included SNVs
(22%); indels (10%); gross chromosomal losses, gains and LOH (33%); sub-arm copy
(focal) number abnormalities (20%) and SVs/gene fusions (44%). Overall, we reported
a mean of three pathogenic or likely pathogenic (P/LP) somatically-acquired sequence
variants per case (range 0–14) in addition to ploidy alterations, such as gross chromosomal
gains and losses and chromosome arm-level regions of copy neutral LOH (CNLOH). Two
brain tumors had no reportable P/LP findings despite pathology review indicating adequate
tumor tissue. The prevalence of variants deemed P or LP in hematological malignancies,
brain tumors, and non-CNS solid tumors, affected by diverse mutational mechanisms, were
consistent with other recent pediatric cancer genomic studies(8,14,15,20–22) (Fig. 2A,
Supplemental Table S2).
Identification of gene fusions, enhancer hijacks, microdeletions
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SVs causing gene fusions or enhancer hijacking are important drivers of pediatric
cancers(23–25), yet they are challenging to detect by WES as SV breakpoints are most
often located in non-coding regions of the genome. Consistent with this finding, we showed
previously that inclusion of WGS in the study of pediatric cancer genomes significantly
improves the detection of driver gene alterations when compared to WES alone(14). Using
the three-platform sequencing approach, we identified in-frame gene fusions in 90 tumors
(36%) representing 44 distinct gene-pairings and 34 distinct fusion driver genes of which 23
were diagnostic for a specific cancer type or subgroup. Thirty of the 34 conferred a clear
or potential diagnostic, prognostic or therapeutic utility (Fig. 2B, Supplemental Figs. S2 and
S3, Supplemental Table S2). For example, brain tumor SJBT030081, originally classified as
a high-grade glioma, was found to harbor an MN1-CXCC5 gene fusion and thus reclassified
as a CNS high-grade neuroepithelial tumor with MN1 alteration, an entity only recently
described(26). Five of the rare fusions shown in Fig. 2B (shown in red) were in patients with
very rare tumor types (as shown in Fig. 1E).
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In an additional 21 tumors (8%), combined WGS and RNA-Seq analysis enabled detection
of 10 distinct enhancer hijacking translocations, wherein an SV brings a transcriptionally
active locus into close proximity to an oncogene thereby driving its expression. We
correlated outlier oncogene expression with SV breakpoints from WGS data to facilitate
the accurate detection of enhancer hijacking events, which ranged from 0–716 kb up or
downstream of the target oncogene with outlier expression (see Methods, Supplemental
Fig. S4, Supplemental Table S3). Enhancer hijacks included well-characterized events such
as IGH@-CRLF2, TCR@-LMO2, IGH@-DUX4, IGH@-EPOR, and DDX31@-GFI1B.
In addition, there were less-well-characterized enhancer hijacks such as two instances
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of CDK6@-MECOM in acute myeloid leukemia, which may have a negative prognostic
impact(27), and a novel TLX3-activating translocation in a T-acute lymphoblastic leukemia
(T-ALL) sample, as described below (see below, “Disease relevance of novel somatic
variants“).
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Acute leukemias are susceptible to small microdeletions, resulting from off target
recombinase activating gene (RAG)-dependent effects(28,29). Detection of these deletions
can be of prognostic significance, as is the case with IKZF1 in B-ALL, where intragenic
deletions are associated with a poorer outcome(30). However, intragenic microdeletions can
be difficult to detect using WES because exons rarely capture deletion breakpoints and their
identification must rely on subtle changes in depth of coverage(31,32). Consistent with this
notion, we previously observed that single nucleotide polymorphism (SNP) array or WES
have limited power for detecting focal and exon-poor CNAs due to insufficient physical
space for robust detection of read-depth changes(14,33). Using WGS data, we detected
small intragenic deletions involving as few as one or two exons in cancer-relevant genes
in 38 tumors (15%), with all but six being leukemias (Supplemental Table S4). Twentysix genes were affected, including those expected(28), such as BTG1, CDKN2A, ETV6,
RAG1, TCF4, IKZF1, and TP53 among the most commonly involved. Several clinically
relevant genes that are less commonly observed as targets of microdeletion, including
CREBBP, SH2B3, USP9X, FBXW7, and NR3C2, were also impacted. The majority of
these microdeletions (38 of 53 total events; 72%) involved loss of a single gene copy and
thus would have been difficult to detect using WES.
Mutation signatures and etiology of pediatric tumors
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The whole genome mutational landscape of a tumor records its natural history and reflects
the environmental and endogenous exposures that have contributed to tumor initiation
and progression(34,35). To elucidate the mutational landscape of pediatric cancers, we
evaluated WGS tumor data for the relative proportions of mutation signatures reported by
Alexandrov(36) (Supplemental Table S5). In addition to well-known mutational processes
such as spontaneous deamination (Signature 1) evident in nearly every patient, Signatures 2
and 13 reflecting activation induced cytidine deaminase (AID) and apolipoprotein B mRNA
editing enzyme, catalytic polypeptide-like (APOBEC) activity were present in several of BALL cases(37,38); Signatures of ultraviolet radiation exposure were present in four B-ALL
samples and a cutaneous melanoma (see also(15)) and three tumors exhibited signatures
6 and 15, indicating mismatch repair (MMR) deficiency as well as signature 10, which
is associated with mutated DNA polymerase epsilon (POLE). Six tumors harbored high
levels of signature 18, thought to arise from DNA damage induced by reactive oxygen
species (ROS) with one tumor exhibiting bi-allelic loss of MUTYH, the glycosylase that
executes the first step in repair of ROS-induced mutations. The roles of the MMR deficiency,
and POLE and ROS signatures in disease pathogenicity are described further below (see
“Disease relevance of germline variants”).
Disease relevance of novel somatic variants
Most pediatric cancer genomes harbor a limited number of somatic alterations, many of
which are non-recurrent making it difficult to ascertain pathogenicity. Visualization of

Cancer Discov. Author manuscript; available in PMC 2022 April 03.

Newman et al.

Page 6

Author Manuscript
Author Manuscript

these variants in the context of large-scale public data was essential to classify some of
these challenging N of 1 events. We illustrate this process with two examples. The first
case, SJTALL030071, is a T-ALL that harbored a translocation t(5;8)(q35q24) linking an
intergenic region on 8q24, 1 Mb distal of MYC, to an intergenic region 29 kb distal to
TLX3, a known driver of T-ALL(39). The copy number profile of this tumor showed
an 18 Mb duplication of the 8q24->8qter region that did not include MYC (Fig. 3A);
but did include the NOTCH MYC enhancer(N-Me)(40) that is known to activate MYC
in T-ALL. Indeed, N-Me activity was confirmed by the high level of enhancer RNA
and MYC expression in this tumor. The translocation juxtaposed N-Me 29 kb upstream
of TLX3 leading to elevated TLX3 expression (Fig. 3B). Moreover, using SNP markers
in the DNA at the TLX3 locus, we demonstrated allele-specific expression (ASE) in
the RNA, consistent with activation by a cis-acting regulator (Fig. 3C). Consistent with
these findings, SJTALL030071 clustered by tSNE analysis among other TLX3-driven TALLs from the National Cancer Institute-Therapeutically Applicable Research to Generate
Effective Treatments (NCI-TARGET) cohort (Fig. 3D). Altogether, these data suggested
mechanistic similarity to known enhancer hijack events linking TLX3 to T-cell receptor
enhancer loci(39,41) and accordingly we classified the translocation as LP.

Author Manuscript

The second case, SJBALL030052, is a B-ALL with a complex structural variant that
exhibited DNA and RNA evidence of a novel fusion including exon 2 of ETV6 with
exon 2 of FOXO3 (Fig. 3E). The impact of this fusion was not initially clear as it could
conceivably result in ETV6 loss of function (LOF) or in a gene fusion functionally similar
to ETV6-RUNX1. To gain further insights, we compared the RNA-Seq gene expression
profiles between our B-ALL sample and the publicly available RNA-Seq profiles from
1,988 other childhood B-ALL cases(42). SJBALL030052 clustered with the ETV6-RUNX1
subgroup (Fig. 3F), suggesting that the fusion impacted gene expression similarly to ETV6RUNX1. We thus classified the novel fusion as LP, which supported this patient’s clinically
determined standard risk classification.

Author Manuscript

Across all 253 tumors, 65 (25%) harbored a total of 89 genetic alterations that were
considered rare or unreported in the tumor type being investigated (Supplemental Table S6).
For example, we found AKT1 activating variants in two T-ALL patients, SJTALL030064
and SJTALL030134. AKT1 represents a targetable oncogene in epithelial cancers but it
is only very rarely altered in T-ALL and its role and efficacy as a therapeutic target
have yet to be investigated in this cancer type. These rare events were often suggestive
of unusual mechanisms of activation of an oncogene or signaling pathway. For example,
USP9X LOF was found in two cases, and potentially activates JAK/STAT signaling(43). Of
these 90 rare or novel events, 23 (26%) were SVs predicted to generate fusions or enhancer
hijacks identified by WGS and RNA-Seq analysis. These observations demonstrate that the
spectrum of cryptic intergenic events continues to expand through use of these combined
non-biased genomic approaches.
Germline cancer predisposing variants
We analyzed 156 cancer predisposition genes using germline WES and WGS data for
the 300 patients who consented to return of germline results. This list included 63 genes
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associated with moderate to high cancer penetrance(9), as well as 93 additional genes,
approximately half of which are associated with autosomal recessive cancer predisposing
conditions (Supplemental Table S7). We classified variants according to the American
College of Medical Genetics and Genomics (ACMG) and the Association for Molecular
Pathology (AMP) 2015 germline variant interpretation guidelines(44). Germline P, LP or
variants of uncertain significance (VUS) among the 63 moderate/highly penetrant genes
were reported back to providers and patients. For the remaining 93 genes, only P or LP
variants were included in the final clinical reports.
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We identified 58 germline P or LP variants affecting 29 genes in 55 (18%) of 300 patients
(Fig. 4A, Supplemental Table S8) and 420 VUS affecting 111 genes in 230 (77%) patients
(Supplemental Table S9). The prevalence of P/LP variants ranged from 10% for patients
with hematologic malignancies to 40 – 50% for those with retinoblastoma and other solid
tumors (Fig. 4B). Thirty-two (55%) of the germline P/LP variants affected genes not
generally associated with the patient’s tumor type, such as a germline mutation in WT1
in a patient with B-ALL (SJBALL030057) or a germline mutation in BRCA2 in a patient
with a diffuse intrinsic pontine glioma (SJHGG030328, Supplemental Table S8). Therefore,
if targeted germline gene panels relevant to the patient’s tumor type had guided testing, these
variants might have escaped detection as many of the panels would not have included the
affected genes.
Disease relevance of novel germline variants
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An integral component of our germline variant pathogenicity classification involved
simultaneous review of paired tumor-normal data to determine the molecular impacts
of germline variants on RNA splicing and expression, tumor mutation signatures and
tumor mutation burden (TMB). For example, transcriptome data from Ewing Sarcoma,
SJEWS030332, harboring a novel BAP1 intronic variant at the −3 position of exon 5
(NM_004656.3: c.256–3C>A), revealed evidence of intron retention in the tumor relative
to other Ewing Sarcoma samples in the study. Fisher’s Exact test showed a significant
difference in number of variant-bearing RNA-Seq intronic reads relative to PCR-free tumor
WGS (p=0.047) (Fig. 4C). Intron retention, unveiled by the use of tumor RNA data,
provided sufficient evidence to classify this novel germline variant as LP.

Author Manuscript

A patient with B-ALL, SJBALL030144, presented with café au lait macules but no coding
mutations to explain this clinical phenotype. Analysis of tumor RNA data revealed that a
germline NF1 variant at the +3 position of exon 45 (NM_000267.3: c.6858+3A>G) caused
skipping of exon 45, which is predicted to lead to out-of-frame translation of the NF1
protein (Fig. 4D). This variant was classified as LP. The opposite conclusion was obtained
for a germline APC variant (NM_000038.5: c.449A>G) in patient SJST030310. Analysis at
an external clinical laboratory predicted creation of a de novo splice site with subsequent
LOF; however, review of tumor transcriptome data provided no evidence of altered splicing,
and we thus classified this variant as a VUS (Supplemental Fig. S5).
TMB and mutation signatures derived from WGS were used to establish the roles of
germline variants in generating the molecular phenotypes observed in some tumors.
Tumors were classified as hypermutators based on a TMB >10 mutations per Mb and
Cancer Discov. Author manuscript; available in PMC 2022 April 03.
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ultra-mutators with >100 mutations per Mb(45). Two cases (SJHGG030335, SJHM030291)
harbored germline biallelic PMS2 pathogenic variants leading to tumors that exhibited
TMB and mutational signatures consistent with MMR deficiency (Supplemental Table
S5). SJHGG030335 harbored >100 mutations per Mb due to an acquired POLE S459F
pathogenic somatic variant. The POLE-related mutational signature was also exhibited by
this tumor.
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Finally, SJST030211, a squamous carcinoma of the lip, exhibited a hypermutator phenotype
corresponding to COSMIC signature 11, which is linked to temozolomide treatment
(Supplemental Fig. S6A,B). Consistent with this finding, this patient had received prior
therapy with temozolomide for a low-grade glioma and had no detectable mutations in
MMR genes in the germline or the squamous carcinoma. Thus, the mutator phenotype was
caused by therapy, with this information obviating the need for follow-up germline testing
for the patient and family.
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As more children with cancer undergo gene panel or multiplatform sequencing, an
increasing number of pathogenic germline variants are being identified in genes not
generally associated with the patient’s tumor type, and in some cases, these variants
are associated with adult-onset conditions or autosomal recessive cancer predisposition
syndromes(4,5,9,22,46). Nevertheless, it remains poorly understood whether or how these
germline variants contribute to the pathogenesis of pediatric cancers. Therefore, we reviewed
all germline P/LP variants in the context of each patient’s tumor type to determine whether
the germline variant might have played a causal role based on the molecular phenotypes
observed in the tumor. We considered a germline variant relevant to development of the
child’s tumor if the gene had a known association with the child’s tumor type, or if there
was specific molecular evidence supporting a functional consequence of the mutation in the
tumor. If neither of these criteria were met, the relevance of the variant in the tumor was
considered to be unknown (Supplemental Fig. S7).
Using this scheme, 32 of 58 (55%) germline P/LP variants affecting 15 genes were
characterized as relevant to tumor formation (“Disease Related”, Supplemental Table S8,
Fig. 5). Most of these genes have known relationships with pediatric cancer, such as
RB1 in retinoblastoma (RB), NF1 and PMS2 in glioblastoma (GBM), and PTCH1 in
medulloblastoma. Examination of tumor WGS and RNA-Seq data, protein expression and
the literature enabled classification of disease relevance in several N of 1 cases, illustrated in
the following examples.
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First, we observed a missense germline TP53 variant, (A161T), in patient SJNBL030203
with NBL. Although prior studies have suggested that this variant is damaging with a
dominant negative LOF effect(47–49), NBL occurs only very rarely (~1%) in individuals
with pathogenic germline TP53 variants(50). Further, like most NBL(51), this patient’s
tumor retained the wild-type TP53 gene copy. However, examination of tumor RNA-Seq
data revealed expression only of the variant allele (Fig. 6A). Together these data suggest that
there is transcriptional silencing of the wild-type gene copy, a mechanism not yet described
in NBL, and we considered this germline variant relevant to the child’s tumor.
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Patient SJRB030050 with RB harbored a germline MUTYH founder variant (G396D, Fig.
6B) that was rendered homozygous in the tumor through CNLOH. The TMB was in the
upper quartile among all RB tumors in the G4K study, as well as a larger set of RB
tumors evaluated through the Pediatric Cancer Genome Project (PCGP) (Fig. 6C). Notably,
over half of this tumor’s mutations were attributable to the ROS Signature 18 (Fig. 6D).
These features indicate that the loss of MUTYH function contributed to the mutational
processes in this tumor. As a result, the germline MUTYH variant was classified as relevant
to RB development in this patient. In two other patients harboring the same germline
MUTYH founder mutation (Supplemental Table S8), the variant was considered of uncertain
relevance to disease because there was no loss of the wild-type allele and no ROS mutation
signature in their tumors.
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Two patients harbored a single heterozygous mutation in one of the MMR genes
characteristic of Lynch Syndrome (LS; also known as hereditary non-polyposis colon
cancer). Patient SJHGG030336 with GBM harbored a germline MSH2 variant (N653fs)
and patient SJBT030067 with an unusual adenocarcinoma of the pineal region of the brain
harbored a PMS2 variant (S46I). Neither tumor exhibited mutation or loss of the respective
wild-type gene copy. Nevertheless, the MSH2-mutant glioblastoma (SJHGG030336) was
hypermutated (Fig. 6E) and exhibited a mutation signature associated with microsatellite
instability (MSI, Fig. 6F), consistent with the LS phenotype. Based on the high TMB and
mutation signatures, immunohistochemical staining of this child’s tumor was performed,
revealing absent MSH2 and MSH6 expression (Fig. 6G, top), and confirming a deficiency in
MMR. The germline MSH2 N653fs variant was thus deemed relevant to this child’s GBM.
In contrast, the pineal adenocarcinoma in patient SJBT030067 did not exhibit hypermutation
(Fig. 6E) or the mutation signature of MSI (Fig. 6F) and it retained PMS2 expression (Fig.
6G, bottom). Therefore, the disease relevance of the germline PMS2 variant to development
of this child’s adenocarcinoma remained uncertain.
Finally, patient SJNBL030339 with NBL harbored a pathogenic germline variant in
SMARCA4 with focal deletion of the wild-type allele observed in the tumor (Fig. 5). The
oncogenic potential of germline SMARCA4 variants is known to predispose to small cell
carcinoma of the ovary and less commonly to rhabdoid tumor(52), but it has not been linked
to NBL. However, our finding raises the possibility that SMARCA4 represents a target
for mutational inactivation in NBL. Consistent with this notion, SMARCA4 is expressed
in neural tissues and somatic bi-allelic SMARCA4 variants are present in 1% of NBL
tumors(53). Further, the literature includes two cases of NBL with pathogenic germline
SMARCA4 variants(4,54). Taken together, these data strengthen the association between
germline SMARCA4 variants and predisposition to NBL.
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Management implications resulting from genomic findings
Although the G4K study was non-therapeutic by design and thus not intended to match
patients to a targeted therapy, we sought to investigate whether genomic findings obtained
from three platform sequencing would inform diagnosis, risk stratification, cancer treatment
and/or genetic counseling of the patient and family(6,55,56). We deemed variants as
therapeutically actionable or potentially actionable if they were classified as P/LP from
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a somatic perspective and they or their downstream pathways could be targeted(6). To
make these determinations, we used available evidence(46,57,58), including U.S. Food and
Drug Administration approved targeted therapies, eligibility for treatment on a clinical trial
based on NGS results and other professional guidelines or associated information (https://
www.oncokb.org/; https://civicdb.org/home).

Author Manuscript

In total, 218 of 253 patients (86%) who underwent sequencing of paired tumor and normal
tissues had at least one finding that was diagnostic (53%), prognostic (57%), therapeuticallytargetable (25%), involved in cancer predisposition (18%) or some combination of these
features. (Fig. 7A, B; Supplemental Table S10). Among the somatic alterations, the
preponderance of targetable abnormalities included gene fusions or hotspot mutations in
kinases including BRAF, ALK, MET and ABL1. We also detected several indirectly
targetable mutations/fusions affecting genes upstream of the JAK-STAT pathway involving
EPOR, CRLF2, SH2B3 and USP9X. Fusions of EPOR and CRLF2 and truncations of
SH2B3 and USP9X are associated with Philadelphia chromosome-like B-ALL(57,59),
the treatment of which with JAK1/2 inhibitors is under investigation (NCT03117751,
NCT02723994).

Author Manuscript
Author Manuscript

At the time of diagnosis, the majority of pediatric cancer patients, including those in the
G4K study, are placed on IRB-approved clinical trials. However, 78 G4K patients with
sequenced tumors presented with relapsed or metastatic tumors for which there was no
clinical trial available, or they developed metastatic, relapsed or refractory disease during
the course of the study. Thus, approximately one third of the patients were eligible for
a change in therapy, including an NGS-directed agent. Thirty-two (41%) of the tumors
in this relapsed/refractory group harbored one or more targetable or potentially targetable
lesions or a targetable mutation signature. Twelve patients (38%) received a targeted agent
matched to their tumor’s genetic lesion or mutational signature (Supplemental Table S11).
Five of these 12 patients responded to the genomics-directed therapy (one patient with AML
[complete response], one with melanoma [partial response], two with glioblastoma [stable
disease, SD], and one with craniopharyngioma [SD]) (Fig. 7C). The two patients whose
glioblastomas exhibited mutational signatures consistent with mismatch repair deficiency
were treated with checkpoint inhibitors with one of these two surviving for two years under
this therapy, while exhibiting no significant side effects. Two patients remain alive at the
time of writing: SJAML030286, whose AML harbored a somatic FLT3 internal tandem
duplication and was treated with sorafenib and gilteritinib-containing regimens for a total
of 12 weeks followed by allogeneic stem cell transplantation; and SJBT030073, whose
multiply recurrent craniopharyngioma harbored a somatic PIK3CA mutation and was treated
with everolimus for 172 weeks. This patient’s tumor progressed and was subsequently
partially resected with sequence analysis of the resected tumor showing loss of the PIK3CA
variant.
All participants with P/LP germline variants have undergone genetic counseling and
first-degree relatives have been offered clinical evaluation and targeted genetic testing;
more distant family members have been encouraged to pursue counseling in their home
communities. Although cascade testing is still ongoing, 27 of 77 (35%) tested individuals
from 31 families have been found to harbor a cancer predisposing germline variant
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(Supplemental Table S8) and all have been provided with recommendations for cancer
surveillance and when appropriate, risk reducing measures. To date, 19 of 58 germline P/LP
variants (33%) have been confirmed as inherited, while 12 (17%) are de novo in origin. The
remaining 27 are of unknown inheritance.
Comparison to gene panels

Author Manuscript

We next sought to determine what proportion of the events found by the three-platform
sequencing approach would also be detected by commercially available gene panels. For this
analysis we selected four commonly used somatic panels: Foundation One CDx, Foundation
One Heme, Oncomine v3, and Oncokids Hotspot. All four panels detect coding SNVs and
indels, including exonic ITDs and focal copy number alterations (CNAs). For a defined
set of genes, Foundation One CDx detects common intronic translocation breakpoints in
DNA and the other panels detect fusion transcripts in cDNA. For comparison of novel
gene fusions, we required that the panel include only one partner gene of the fusion pair
discovered in our data set (see Methods, “Comparison to gene panels”, Supplemental Table
S12–14, for further details).
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We observed that 42 – 84% of the evaluable P/LP SNVs/indels/ITDs/fusions/SVs and focal
CNAs could have been detected by one or more of the panel designs (Supplemental Tables
S12,13). Oncomine, applied to pediatric hematologic malignancy cases, covered the G4K
variants least efficiently. This is not surprising since the panel is optimized for evaluation
of adult solid tumors. The pediatric-specific Oncokids panel fared better covering 65%
and 74% of reported abnormalities for brain/CNS tumors and hematologic malignancies,
respectively. The best performing panel was Foundation Heme when applied to pediatric
hematologic malignancy cases, covering 84% of reported abnormalities. Confining our
analysis to only include clearly targetable mutations (i.e., omitting potentially targetable
mutations such as KRAS G12D, EWSR1-FLI1 and others as defined in Supplemental Table
S2), panel coverage ranged from 39 to 85% with Oncomine applied to pediatric hematologic
malignancies detecting the fewest alterations and Foundation CDx applied to solid and brain
tumors detecting the most (Supplemental Table S14).
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On a per patient basis, between 36 – 69% of patients had at least one reported mutation
through G4K that was not covered by one of these panel designs (Supplemental Tables
S13, S14). This number includes abnormalities with a functional impact on the protein
but of no known clinical significance. Considering only those variants with clear clinical
impact, between 18 – 30% of patients had at least one diagnostic, prognostic, therapeutically
relevant or cancer predisposing mutation that was not covered. Interestingly, two of
the 12 patients with relapsed or refractory cancers who received a genomics-specified
therapy harbored variants that would not have been detected by these panels. These
include patient SJMEL030083 with a metastatic melanoma harboring a MAP3K8-GNG2
fusion (treated with the MEK inhibitor trametinib) and patient SJBT030076 whose clear
cell meningioma harbored an EPS15L1-KLF17 fusion (treated with the EGFR inhibitor
erlotinib) (Supplemental Table S11).
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DISCUSSION
Through the G4K study, we performed comprehensive WGS, WES and transcriptome
sequencing of tumor and/or paired normal samples from 309 prospective unselected children
with cancer to quantify the prevalence and spectrum of genomic variants and evaluate
the potential benefits of a three-platform sequencing approach. Several recent reports
have focused on cohorts enriched in children with high risk, relapsed and refractory
cancers(1,3,8,57,58,60,61). The G4K study intentionally differed from these others in that
it was designed to investigate an unbiased cancer cohort, including patients with newly
diagnosed standard risk tumors, as well as those with more aggressive forms of disease,
to specifically ask whether novel insights into the biology of cancer can emerge from
comprehensive sequence analysis of all pediatric cancers.

Author Manuscript
Author Manuscript

Incorporation of whole genome DNA sequencing enhanced the identification of clinically
relevant lesions that are detected inefficiently or not at all by other genomic platforms. WGS
detected inter- and intragenic SV breakpoints, which demarked the location of translocations
and large deletions on whole chromosome scales. Translocations that activated oncogenes
through enhancer hijacking with chromosomal breakpoints up to more than 750 Kb away
from the target oncogene were present in 8% of cases. On a smaller scale, WGS detected
intragenic microdeletions affecting one or two exons in 15% of tumors, some of which
may not be detectable by exome-based copy number analysis, as shown in our previous
study(14). Moreover, the passenger mutations in WGS identified the mutational processes
supporting the role of germline lesions in MMR (MSH2, PMS2) and base excision repair
genes (MUTYH) that contributed to the pathogenesis of several tumors. Taken together, up
to one third of tumors in the G4K study were impacted by oncogenic events detected most
sensitively by WGS. Recent results demonstrate that topologically associated chromatin
domains(62) can be disrupted by focal copy number variation leading to dysregulated
expression of oncogenes and tumor suppressors located in cis, often at long distances from
the genomic event(63,64). These data point toward an increasingly important role in the near
future for WGS combined with transcriptome sequencing in the clinical evaluation of patient
tumor genomes.
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Eighty six percent of patients had at least one finding that was diagnostic, prognostic,
targetable, or indicating an underlying germline predisposition. One quarter of the tumors
analyzed harbored a possible therapeutic target, excluding cases wherein MEK inhibitors
would be an option. Benefit from MEK inhibitors, used downstream of mutant KRAS,
NRAS and NF1, is more difficult to predict, but including MEK inhibitors, our potentially
targetable group would comprise 43% of all tumors tested. While this proportion falls
within the range of recent studies(4,5,8), it is notable given that the majority of patients
on the G4K study had newly diagnosed standard risk cancers, which might be expected to
harbor fewer variants when compared to high risk or relapsed/refractory cases. Potentially
targetable abnormalities consisted mostly of JAK/STAT pathway mutations in B-ALL that
can be treated with ruxolitinib or other JAK inhibitors; high TMB samples that can be
treated with pembrolizumab, ipilimumab or additional check point inhibitors; and kinase
fusions including BRAF in low grade glioma, which may be treated with tyrosine kinase or
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MEK inhibitors. The proportion of patients who respond to these or other therapies remains
to be determined and is an active area of investigation.
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During the course of the G4K study, 78 patients whose tumors were sequenced presented
with or developed metastatic, relapsed or refractory disease with almost half of the
tumors harboring potentially targetable lesions. Therapy was changed for 12 patients based
on tumor genomic data, with one patient moving on to curative allogeneic stem cell
transplantation, and four patients exhibiting prolonged disease stabilization. Recently the
Zero Childhood Cancer Program reported on 38 patients receiving a genomics-specified
targeted therapy, with 31% demonstrating clinical benefit(22), a proportion similar to ours.
Nevertheless, despite favorable clinical outcomes in a limited number of patients, overall
responses were modest across both of these studies. Together, these findings highlight that
we still do not understand the full spectrum of genomic lesions that drive therapy response
in most children with cancer. These findings support our premise that the collection and
interrogation of comprehensive genomic information is critical if we are to further push the
boundaries of cure.
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Revealing an inherited cancer predisposition can impact patient management by informing
genetic counseling, enabling familial genetic testing, facilitating implementation of cancer
surveillance and cancer risk reducing measures, and directing cancer treatment. Our
screening through G4K uncovered germline P/LP variants in 55 patients of whom almost
two thirds would not have been detected based on routine clinical indications for genetic
testing. Importantly, simultaneous assessment of tumor and germline genomes, including
features such as TMB and mutation spectrum, and allele-specific expression, improved
variant classification in several cases. Indeed, we found corroborating evidence in the tumor
that at least half of the germline P/LP variants we reported were likely to be relevant to the
development of the child’s tumor.
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Gene panels designed to match patients with currently available targeted therapies offer
a rapid turn-around time, low expense, deep sequencing coverage, and sparing of tissue
when limited biopsy material is available – all valuable characteristics in the clinical setting.
Moreover, the trend toward adapting panels to capture cDNA addresses the need to detect
fusion transcripts, allowing for the discovery of novel fusion partners of the more commonly
involved oncogenes(65). Thus, for routine standard of care, comprehensive gene panels
address the medical need of the majority of patients. Nevertheless, there is much yet to be
learned about childhood cancer. Among our set of 12 patients with relapsed or refractory
cancers whose therapies were changed based on tumor genomic data, two received therapy
as the result of novel alterations that would not have been detected by the any of the panels
examined. Further, the relevance of a comprehensive view of the mutational landscape in
informing understanding of tumorigenesis and management, even in the diagnostic setting,
should not be underestimated. When evaluating the yield of gene panels in the G4K
cohort, approximately one in five patients harbored a clinically relevant mutation that we
conservatively estimated would have remained undetected using one of the panels examined.
For the G4K patients sequenced at diagnosis, it remains to be determined what impact these
events will have on overall outcomes.
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Despite its potential benefits, comprehensive genomic profiling, such as that reported herein,
is currently beyond the scope of most cancer clinical services for a variety of reasons. First,
obtaining fresh frozen tissue for three-platform sequencing was not feasible for all patients.
For the cancers where only limited biopsy is possible, alternative workflows involving
formalin-fixed paraffin embedded samples may need to weigh the benefits of the breadth
of WES against the coverage depth of a robust panel design. Second, the infrastructure and
computational resources necessary to perform three-platform sequencing are substantial.
Although recent innovations in cloud computing and reductions in the costs of NGS
instruments and reagents are rapidly making whole genome approaches more affordable,
comprehensive genomic profiling will not be standard of care for some time to come.
Third, turn-around time is a major challenge to a comprehensive genomics approach in the
clinical setting. Throughout the G4K study the entire workflow, from analyte preparation
to data analysis, classification, and reporting was under seven weeks for 95% of the
cases. Currently turn-around times are under six weeks, and we are investigating improved
laboratory and computational methods reduce this still further. Finally, as we recently
reported(16), there was a significant overrepresentation of African American patients who
declined participation in the G4K study. While all 53 patients were later offered more
focused germline testing, only 11 chose to pursue such testing. Thus, disparities exist in
the context of cancer genomics and additional efforts are warranted to understand patients’
perspectives and decision making surrounding such testing to enhance future enrollment of
diverse populations.
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In summary, the G4K study provides evidence that three platform sequencing of tumor and
paired normal tissues generates a more detailed picture of the genetic landscape of a tumor,
at times revealing clinically relevant information that would go undetected if one used more
targeted NGS approaches. As genomic sequencing technologies become less expensive and
more widely available, their use will be an important adjunct to gene panels in the evaluation
and management of children with newly diagnosed as well as relapsed or refractory cancers.

METHODS
Patient eligibility and accrual

Author Manuscript

This study was approved by an institutional review board (IRB# Pro00005011) and
conducted in accordance with institutional and ethical guidelines. Over 20 months, 918
patients at St. Jude Children’s Research Hospital were assessed for enrollment in the G4K
study (NCT02530658). Enrollment criteria consisted of availability of a fresh-frozen tumor
sample and a paired normal (i.e., germline) sample. Tumor purity was determined by a
pathologist using visual inspection of a hematoxylin & eosin (H & E) stained section of the
tumor just adjacent to the portion sent for DNA and RNA extraction. For leukemia samples,
tumor purity was determined based on a blast count determined by visual inspection of an
H & E stained bone marrow section or by flow cytometric analysis. A tumor purity >40%
tumor was preferred in order for sequencing. Tumor purity was >40% in all but 16 cases,
where it ranged from 23 – 37%. Nevertheless, sequencing successful in each of these cases.
Three hundred sixty-five patients were eligible to enroll. Patients and their parents met
with a research nurse, trained by certified genetic counselors, who introduced the study and
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answered questions. Patients were provided with written materials describing the study and
a copy of the consent form to review. Interested patients were scheduled for an informed
consent visit during which the research nurse reviewed key concepts, assessed parent and
patient understanding and obtained written informed consent. When possible, patients also
met with an oncologist, clinical geneticist or nurse practitioner to undergo collection of a
full medical history and completion of a physical examination, and with a genetic counselor
who obtained the family history and constructed a three-generation pedigree. A positive
family history was defined as presence of at least one first- or second-degree relative with
cancer diagnosed before age 50, excluding cervical and non-melanoma skin cancers (see
Supplemental Table S15). This same definition was used in our prior report of germline
findings from the Pediatric Cancer Genome Project(9) and it is very similar to those in other
recent reports(66–68).
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Nucleic acid extraction and sequencing
For solid tumors, sample adequacy and tumor cell percentage were assessed using a
hematoxylin and eosin-stained section from a block of tumor tissue adjacent to the one from
which DNA and RNA were extracted. For leukemias, adequacy was based on bone marrow
blast count. Tumor tissue was not available for many patients with RB, craniopharyngioma,
optic pathway glioma and diffuse intrinsic pontine glioma due to safety concerns around
biopsy (see Supplemental Table S1 for more details).
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Nucleic acid extraction, library preparation and sequencing on the Illumina HiSeq
2500/4000 were as described(14) with a single modification. Specifically, in our previous
clinical genomics pilot study, WES was performed using the TruSeq DNA LT Sample Prep
kit (Illumina Inc., San Diego CA), whereas in the present study it was completed using
the Nextera Rapid Capture Exome Kit and the TruSeq Exome kits (both from Illumina).
Samples were named according to the following convention: SJ (St. Jude), Disease code (for
example RB; disease codes are listed in Supplemental Table S1), patient number, sample
type (D1 is first diagnostic sample, D2 is second diagnostic sample, R1 is first relapsed
sample, G1 is first germline sample, etc.). Sequencing coverage and other statistics are listed
in Supplemental Table S16.
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Post-sequencing quality-control (QC) thresholds established during the pilot phase of our
clinical service(14), were as follows: for WGS, ≥40% coverage of coding exons at 45X,
however ~80% coverage at 30x was acceptable upon the Medical Director’s review. For
WES, coverage of coding exons was ideally ≥65% at 45x, but ~80% coverage at 30x was
acceptable upon the Medical Director’s review. For RNA-Seq, ideally ≥15% of coding exons
were covered at 45x, but 20% at 30x was acceptable upon the Medical Director’s review.
Additional sequencing was performed in some samples in order to meet acceptable coverage
QC thresholds.
Variant classification and reporting
WGS, WES and RNA-Seq data were aligned and variants called and annotated using
previously published algorithms(19,33,69,70) and automated pipeline infrastructure(14).
Genome analysts reviewed variant calls and presented each case to a multidisciplinary
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tumor board consisting of representatives from Pathology, Computational Biology and
Oncology. Since our objective was to report SNVs/indels and CNAs from the somatic
and germline context, as well as somatically acquired SVs, we adopted a unified reporting
nomenclature that encompassed every variant type. As a convention, in referring to regional
or focal copy number changes, we use CNA in the somatic context, and CNV in the
germline context. We classified germline SNVs and indels according to the ACMG 2015
guidelines(44) and subsequently adopted the same nomenclature for other variant types. We
reported germline P, LP and VUS found among 63 high-risk cancer predisposition genes,
including those recommended by ACMG v2.0(71) and those for which clinical management
recommendations exist or are under development(44), as well as P/LP variants in 93
additional cancer predisposition genes. Germline CNVs were assessed for their functional
impact on the gene of interest. If a CNV caused a loss of function, we applied the PVS1
tag(72) and if it was rare or absent from databases such as DGV (http://dgv.tcag.ca/dgv/app/
home), we also attached the PM2 tag, allowing us to classify these variants as P/LP in
keeping with germline SNV/indel calls.
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Somatic variants with a clear or likely impact on the function of a cancer-relevant gene
were classified as P or LP, respectively, and those with an uncertain impact were classified
as VUS. Somatic variants classified as VUS were not included in clinical tumor reports.
When assessing the pathogenicity of somatic SNVs/indels, we considered multiple lines
of evidence obtained using functional prediction algorithms and literature mining, as well
as recurrence in the PCGP(20) and NCI-TARGET(15) databases, other pediatric cancer
mutation data in the St. Jude PeCAN portal(73), and adult cancer data from the Catalogue
of Somatic Mutations in Cancer (COSMIC)(74). Whenever possible, we used tumor RNA
data to establish the functional impact for novel SVs by seeking evidence of truncation or
in-frame gene fusion, and for gene amplification or enhancer hijacks, we used these data to
examine gene expression.
We based our assessment criteria for clinical actionability on the system described by
ACMG/ASCO/AMP(56,75). For SNVs/indels we called any variant with Tier IA/B or tier
IIC as actionable as these comprised diagnostic, prognostic and therapeutically-relevant
lesions with a high level of supporting evidence that an oncologist might reasonably act
upon. Several lesions that did not meet this stringent threshold were mostly placed in
Tier IID and labeled as “potentially actionable” (Supplemental Table S2). For CNAs, we
considered Tier 1A/B and 2 variants as actionable(75) and applied these same assessment
criteria to SVs.
Bioinformatics analysis
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Bioinformatics analysis and variant review were as described(14). Briefly, sequence reads
were aligned using BWA(76) for DNA or BWA and STAR via our Strongarm pipeline(77)
for RNA. Sequence variants were called using Bambino(69), DNA SVs using CREST(70),
RNA SVs including ITD using CICERO(78), a local assembly-based algorithm that
integrates RNA-seq read support with extensive annotation for candidate ranking and
available online at: https://www.stjude.cloud/tools/rapid_RNA-Seq), and CNVs and allelic
imbalance with CONSERTING(33). Variants were annotated using the Medal Ceremony/
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PeCanPIE pipeline(19) (available online at: https://pecan.stjude.cloud/pie). We estimated
TMB by counting all exonic and UTR variants that passed manual review by a genome
analyst in addition to high-quality intronic and non-coding somatic variants falling outside
of repeat regions. For genome-wide calculations, we used only somatically acquired high
quality variants whose Fisher’s Exact Test p-value for somatic origin was <0.05. To
calculate mutations per Mb of DNA, we took all high quality somatic variants from
WGS and divided by 1445 Mb - the total amount of genome capable of generating a
mutation call consisting of Tier 1 (coding exons, splice regions and UTRs): 108,721,345
bp, Tier 2 (potential regulatory regions): 163,138,648 bp, and Tier 3 (intergenic and
intronic regions): 1,173,180,850. Tier 4 (repeat regions): 1,448,043,873 were omitted from
the calculation since our mutation calling pipeline masks these regions. For mutational
burden in exome only regions, we used 108.7 Mb as the denominator - the size of Tier
1 regions listed above. B-ALL and T-ALL 2D t-SNE distributions used data and methods
described previously by Gu et al. (2019)(42) and Liu et al. (2017)(41). All additional
analyses used standard parameters unless stated otherwise. Gene expression was quantified
using the Gencode 75 gene model and HTSeq (version 0.11.1)(79) and normalized
between samples using the DESeq2 (version 1.26) variance stabilizing transformation
function(80). SigProfilerSingleSample was used to test for the presence and abundance of
the COSMIC v3.1 Mutation Signatures(36), as described(45). Briefly, samples with 400 or
more mutations (485 samples) were analyzed for 46 of the COSMIC signatures (excluding
23 COSMIC signatures which were rarely detected and manually found to be spurious in
each positive case. Samples with fewer than 400 mutations (583 samples) were analyzed
for a core set of 13 signatures (1, 2, 3, 5, 7a, 7b, 7c, 7d, 8, 13, 18, 36, and 40) which
could be reliably detected in low mutation burden samples and common in pediatric cancers
(Supplemental Table S5).
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Analysis of putative enhancer hijacks
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SJTALL030071 harbored a non-canonical interchromosomal translocation juxtaposing the
N-Me (NOTCH MYC enhancer) enhancer to the vicinity of TLX3 caused upregulation of
the gene. To investigate further the possibility of activation of TLX3 by somatic regulatory
non-coding variants, we analyzed WGS and RNA-seq of this T-ALL to identify cis-activated
genes that have outlier expression using cis-X (version 1.4.0) a computational method
for discovering regulatory noncoding variants in cancer by integrating whole-genome and
transcriptome sequencing data from a single cancer sample(81). cis-X first finds aberrantly
cis-activated genes that exhibit allele-specific expression accompanied by an elevated outlier
expression. For each gene, outlier high expression of a cancer sample of interest was
determined by comparing its expression level to those of reference samples with the same
tissue type. A null distribution of ‘leave-one-out (LOO)’ t-statistic score was established
using the reference samples. This was then used to determine the false discovery rate (FDR)
of the LOO t-statistic score of a cancer sample of interest; those with an FDR < 0.05 were
retained as having significant outlier high expression. A minimum of 20 cases is required for
this analysis.
Data used for reference expression matrix were obtained from publicly available data on St.
Jude Cloud or NCI TARGET to meet the minimum sample size criteria. For T-ALL samples
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such as SJTALL030071, RNA-seq data from 264 T-ALLs profiled by NCI’s Therapeutically
Applicable Research to Generate Effective Treatments (TARGET)(41) was used as the
reference expression matrix for evaluation of outlier expression status. For the remaining
cancer subtypes that harbor candidate enhancer hijacking events (e.g., medulloblastoma
(MB), B-lineage ALL (B-ALL) and acute myeloid leukemia (AML)), reference expression
matrix were prepared by querying the relevant cancer diagnosis and selecting File Type
“Feature Counts” (pre-calculated using Gencode V31) using the Data Browser of Genomic
Platform of the St Jude Cloud(82). Feature counts were subsequently converted to reference
FPKM matrix using DEseq2 for calculating outlier high expression status of samples
presented in Supplemental Table S3. The AML reference expression matrix did not include
therapy-related myeloid neoplasms. The number of samples used to construct the reference
expression matrix for each cancer subtype is recorded in Supplemental Table S3.
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For case SJTALL030071, we identified 18 genes that exhibit both allele-specific expression
and outlier high expression surrounding TLX3 (Supplemental Table S17). None of the
genes other the TLX3 play a known role in T-cell development or cancer. There were
29 consecutive SNPs with heterozygous genotypes in tumor DNA around the TLX3 locus
exhibiting mono-allelic expression in tumor RNA (see Fig. 3C).
Comparison to gene panels
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We selected four commercially available gene panels: Foundation CDx, Foundation Heme,
Thermo Fisher Oncomine v3, and CHLA Oncokids in order to represent the breadth
and diversity of clinical gene panels. Foundation CDx is a large general-use DNA-based
panel, Foundation Heme is a large, combined DNA/RNA panel focused on hematological
malignancies, Thermo Fisher Oncomine v3 is a smaller DNA/RNA panel focused on adult
cancers and Oncokids is a pediatric-specific version of the Oncomine platform used in
support of NCI’s pediatric MATCH trial (see Supplemental Tables 12 footnotes for further
details).
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All four panels are capable of detecting SNVs/indels, gene fusions and focal CNAs at
the gene level. However, gross chromosomal changes cannot be officially reported by
these assays. Additionally, complex copy number abnormalities such as chromothripsis
and regions of loss of heterozygosity are not reported. Of 253 G4K patients, 75 patients
(29.6%), predominantly with heme malignancies, had diagnostic, or prognostic gross
chromosomal abnormalities including hyperdiploidy, hypodiploidy and iAMP21. However,
an additional karyotype, FISH or microarray test could be run to detect these abnormalities.
In order to make a direct comparison of reportable gene-level alterations we omitted gross
chromosomal gains and losses from the analysis.
We arrived at a conservative estimate of how many reported and clinically actionable genes
are not represented on the exemplar panels as follows:
1.

We included both somatic and germline mutations in the comparison since our
combined test reported both.

2.

We used the coding sequence DNA portion of the panel assay for SNVs/indels/
ITDs and focal CNAs. We assumed the observed alteration would have been
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captured and reported at the tumor VAF observed in the G4K patient. This
is especially relevant for CNVs as panels generally only report homozygous
deletions or multiple copy gains.
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3.

We used the RNA panel gene lists combined with intronic sequences designed
to capture recurrent translocation breakpoints for fusions, enhancer hijacks and
intragenic SVs.

4.

We required only one of the partner genes to be present on the panel for gene
fusions. This approach was permissive and enabled a conservative estimate of
how many events might be detected by these technologies; we noted in our
previous study that detection of gene fusions with low expression such as
KMT2A rearrangement and KIAA1549-BRAF benefits from a multiplatform
approach(14).

5.

For enhancer hijacks, we were unable to determine if the translocation
breakpoints that we observed by WGS were featured on current panel designs.
Further, we did not assume outlier expression would be required on the panel
data. As such we took the same approach as for gene fusions, requiring only one
of the partner loci being present on the panel design.

If a G4K variant was covered by a given panel, it was tallied as detected (Supplemental
Table S12). We evaluated all variants within each patient and if one variant was missed by a
given panel, the patient was tallied as a miss by that panel (Supplemental Table S13,14).
Visualization of multi-omics data
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To examine the impact of somatic variants within tumors, we used visual exploration of
aggregated multi-omics data from PCGP, TARGET and other studies(15,20,41,42) using
GenomePaint (https://genomepaint.stjude.cloud/).

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF SIGNIFICANCE
Pediatric cancers are driven by diverse genomic lesions and sequencing has proven
useful in evaluating high risk and relapsed/refractory cases. We show that combined
whole genome, exome, and RNA-sequencing of tumor and paired normal tissues enables
identification and characterization of genetic drivers across the full spectrum of pediatric
cancers.

Author Manuscript
Author Manuscript
Author Manuscript
Cancer Discov. Author manuscript; available in PMC 2022 April 03.

Newman et al.

Page 27

Author Manuscript
Author Manuscript
Author Manuscript

Figure 1. Patient accrual and demographic data.
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A. Consort diagram depicting patient accrual into G4K. Note: (a) Three patients were
removed from the study when pathology revealed no cancer (1); the patient died before a
germline sample could be collected (1); or the patient declined return of germline results and
there was insufficient tumor for sequencing (1). B. Age distribution of patients. C. Number
of patients with newly diagnosed, relapsed or refractory tumors, or no tumor available
for sequencing, broken down by major tumor type. D. The distribution of cancer types
represented in the G4K cohort (top) compared to the distribution of pediatric cancers in the
NCI Surveillance, Epidemiology and End Results (SEER) program (bottom). E. Eighteen
rare tumor types found in the G4K cohort present at less than 2 per million children annually
in the United States
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Figure 2. Somatic findings in the 253 analyzed tumors.
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A. Bar charts showing the numbers and relative contributions of mutational mechanisms
affecting cancer genes in the tumors analyzed through G4K. The top 25 mutated genes for
hematologic, CNS and solid tumors are shown as are gene fusions or enhancer hijack events
for singletons in CNS and Solid Tumors. B. Gene fusions and enhancer hijacks detected
in G4K samples. Number of samples with a given fusion are indicated in the left most
column followed by the genes/loci involved and the diseases in which they were detected
(see Supplemental Fig. S3 for schematics depicting the 20 rare fusions). Black or red tiles
indicate whether the identified gene fusions or enhancer hijacks have a clear or likely
clinical utility, arranged into three columns indicating diagnostic (stethoscope), prognostic
(patient chart), and therapeutically-relevant (target) categories. In the right most column
(question mark), tiles indicate lesions with an unknown clinical utility, but considered
biologically relevant to the tumor. Red disease names and tiles were identified in the rare
tumors as shown in Fig. 1E. Disease abbreviations and additional details regarding SV
classifications and literature citations can be found in Supplemental Table 2.
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Figure 3. Using multi-omics data to interpret pathogenicity of structural variants.
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A. GenomePaint plots showing two regions, chr8:128500000–130600000 (top) and chr5:
170710000–170790000 (bottom) [hg19] from SJTALL030071. Both panels consist of the
RefSeq gene model in green with MYC and TLX3 highlighted by red boxes; orange
bars show regions of copy number gain supported by increased whole genome sequencing
coverage plotted as the blue histogram immediately below. Grey lollypops marked t(5;8)
indicate the position of the translocation breakpoint. RNA-Seq coverage is shown below
the whole genome coverage histogram. Additional data from TARGET is also shown with
narrow red bars representing regions of copy number gain and grey lollypops representing
structural variant breakpoints surrounding the TLX3 locus. A region or recurrent copy
number gain in TARGET samples is adjacent to the chromosome 8 breakpoint in
SJTALL030071. Generally high but non-specific RNA-Seq coverage at this locus suggests
a region of high transcriptional activity (distal MYC enhancer) is brought into proximity
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of TLX3 by the translocation. B. A rank-order plot of TALL from TARGET showing
expression levels of TLX3 mRNA in a set of TLX3-activated tumors compared to tumors
in which TLX3 was not activated. SJTALL030071 TLX3 expression (red dot) groups with
the activated set. C. Allele-specific expression of the TLX3 locus in SJTALL030071. The
tumor DNA (top row) shows a series of heterozygous alleles in the TLX3 locus (blue and
red stacked bars show relative variant allele fraction from WGS data). In the RNA-Seq
data (second row) expression of only one allele is observed. RNA coverage, read counts
at each allele, are shown numerically (third row). Beneath the read counts, black lines
map the locations of the alleles to the chromosome 5 coordinates surrounding TLX3 locus.
Beneath the coordinate line, the location of the SJTALL030071 translocation breakpoint
is indicated. D. Two-dimensional t-SNE plot of RNA-Seq-derived gene expression data
from 264 T-ALL samples(41). Major T-ALL subgroups are indicated on the plot with
SJTALL030071 localizing among the TLX3 cluster, as shown by the black arrow. E.
Schematic representation of an ETV6-FOXO3 fusion found in SJBALL030052 joining the
region N-terminal to the ETV6 sterile alpha motif domain (green) with oligomerization
interfaces (red) and ETS domain (purple), with the C-terminal FOXO3 forkhead binding
(green), KIX-binding (purple) and transactivation domains (red). F. Two-dimensional t-SNE
plot of RNA-Seq-derived gene expression data from 1,988 B-ALL samples(42). Major
subgroups are indicated on the plot with SJBALL030052 localizing to the periphery of the
ETV6-RUNX1 subgroup, as shown by the black arrow.
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Figure 4. Germline variants and assessment of variant pathogenicity based on RNA data.
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A. Numbers of germline P/LP variants, broken down by gene and tumor type. B. Proportions
of germline P/LP variants, broken down by tumor type. C. BAP1 intron 4 retention in
SJEWS030332 compared to other G4K Ewing sarcoma cases. Each blue histogram shows
hg19-aligned RNA-Seq coverage relative to the BAP1 gene model in green (note that
BAP1 is on the negative strand). The position of the exon five splice acceptor mutation is
indicated by the red dotted line. Increased read coverage in the SJEWS030332 (bearing a
mutation at the −3 position of exon 5) intron relative to the three other samples indicates
intron 4 retention (black arrow). Inset histograms show the relative proportion of reference
and variant alleles in tumor-derived WGS and RNA-Seq in grey and purple, respectively.
Corresponding read counts are WGS: 32G/21T (40% variant allele) and RNA 2G/28T (93%
variant allele). Above the RNA coverage plots a schematic of the BAP1 protein is shown
with the location of the splice variant leading to protein truncation marked. D. NF1 exon 45
skipping in SJBALL030144. The blue histogram shows RNA-Seq coverage relative to the
NF1 gene model in green. Canonical splices are shown as light blue links between exons
and a non-canonical splice is shown in mauve. The height of mauve and blue lollypops is
proportional to the number of splice junction reads detected plotted on a log scale on the
y-axis. The purple bar indicates the position of the NF1 exon 45 splice acceptor mutation.
Exon 45 expression is diminished relative to flanking exons and a non-canonical splice
linking exons 44 and 46 is observed indicating an exon skipping event.
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Figure 5. The impact of somatic variation in establishing disease relevance of deleterious
germline variants.
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Each row represents a unique patient. From left to right the columns are as follows:
‘Case ID’, the last 4 digits of the patients’ IDs (compare Supplemental Table 8. Column
A). ‘Diagnosis,’ gives the disease code used internally (compare Supplemental Table S8,
Column B). Note, matched superscripts indicate mutations in the same patient. ‘Germline
Variant’ lists the gene and amino acid change. Germline Testing Indicated, signifies patients
whose cancer or other phenotypic characteristics suggested the patient and possibly the
family should undergo germline testing (black tiles). ‘Germline Genotype,’ gives the
genotype of the variant indicated in the Germline Variant column. ‘Second Hit Category’
gives the genetic configuration of any genetic or epigenetic alterations affecting the
remaining wildtype gene copy in the tumor. ‘Molecular Phenotype’ pertains to evidence
in the DNA sequence of the tumor as to the activity of the germline variant. Molecular
phenotypes included features such as splice aberrations visible in the RNA-Seq data
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and mutation signatures. Tumor second hits and molecular phenotype were not available
for some patients due to absence or inadequate tumor for testing (see Methods). The 5
columns of tiled cells are sorted to group germline mutations by ‘Disease Related’ and then
secondarily by ‘Germline Testing Indicated’.
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Figure 6. Evaluation of germline and tumor data to establish disease relevance.
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A. P53 A161T is a weakly functional likely pathogenic p53 variant in SJNBL030203. Six
markers, including the germline variant C>T at chr17:7578449 (demarked by upside down
triangle) are represented by 3 rows of vertical bars. The bars are colored red and blue to
show the allele fractions in WGS data. The rows indicating germline and tumor DNA show
most positions as heterozygous with both red and blue portions. In the RNA, all markers are
mono-colored indicating that only one allele is expressed. At the location of the germline
variant (C>T), the bar is completely red, indicating that only the variant allele is expressed,
suggesting that the wild-type allele is transcriptionally silenced. B. A pathogenic MUTYH
germline founder mutation, G396D, in RB patient SHRB030050. C. The tumor mutation
burden (TMB) for SHRB030050, from WGS data, is in upper quartile compared to other RB
patients including those from St Jude Cloud. Box includes the 2nd to 3rd quartiles; horizontal
bar within box is median. D. Mutation signatures from WGS data from RB patients
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available in G4K and from the Pediatric Cancer Genome Project in the St Jude Cloud
resource (https://www.stjude.cloud/). Sixty percent of tumor mutations in SHRB030050
are attributable to damage by reactive oxygen species (ROS). E. TMB plots of brain and
hematologic tumors. The three tumors that are hypermutated (those with >10 mutations/Mb)
are labeled with patient ID and the genes that were mutated to cause hypermutation. A
fourth brain tumor with a TMB close to median was heterozygous for mutation of PMS2.
The two hypermutated patients with PMS2 carried compound heterozygous mutation of
the gene. The patient with the highest TMB also carried a S459F mutation of POLE.
F. Mutation signatures of the patients in panel (E). G. Immunohistochemical staining for
the indicated mismatch repair proteins in the brain tumors of patients SJHGG030336 and
SJBT030067. Top. Infiltrative astrocytoma with severe cytologic atypia, mitotic activity, and
necrosis; diagnostic of glioblastoma. Immunohistochemistry for mismatch repair proteins
exhibited loss of MSH2 and MSH6, but retained staining in stromal elements. Bottom.
Gastrointestinal-type adenocarcinoma arising in malignant mixed germ cell tumor. Staining
for mismatch repair proteins demonstrated retained expression of MSH2, MSH6, PMS2, and
MLH1. All images are 40X magnification; scale bars represent 40 microns.
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Figure 7. Clinically actionable findings.
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A. Tile plot summarizing clinically actionable findings in the 253 patients who had both
tumor and normal tissues sequenced. Each tumor is represented as a row and is grouped
according to major tumor type. Columns represent the presence (blue) or absence (white)
of a diagnostic (stethoscope), prognostic (patient chart), therapeutically-relevant (target) or
cancer predisposing mutation (pedigree). B. Tumors with targetable (Tier 1 and 2, green)
or potentially targetable (blue) lesions, categorized by the affected gene, identified by the
three-platform sequencing approach. Additional information can be found in Supplemental
Tables S2, S10. C. Swimmer plot depicting patients receiving a targeted therapy matched to
their tumor genetic lesion. Each bar is one patient, with the disease as labeled. Pink bars,
patient is alive; blue bars, patient is deceased. Best response on the targeted therapy is as
labeled. CR, complete response; PR, partial response; SD stable disease; PD, progressive
disease. The drugs used are labeled adjacent to each bar. See Supplemental Table S11 for
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further details. MPAL, mixed phenotype acute leukemia; B-ALL, B-acute lymphoblastic
leukemia; T-ALL, T acute lymphoblastic leukemia; AML, acute myeloid leukemia.
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